Phase 1 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People who are willing and able to sign a dated consent form
- People who are well enough to carry out daily activities with little or no limitation (based on a standard performance scale rated 0 or 1)
- People whose heart, liver, kidneys, and bone marrow are functioning well enough to meet the trial's requirements
- Dose Escalation part of the trial: People who have a confirmed solid tumour cancer that has spread or cannot be removed with surgery, and where standard treatments have stopped working or no standard treatment exists
- Expansion part of the trial: People with a confirmed diagnosis of one of the following advanced cancers — MSS colorectal cancer who have not previously had PD-(L)1 immunotherapy; or MSS endometrial cancer, renal cell carcinoma, or non-small cell lung cancer where a prior PD-1 immunotherapy has stopped working — and who have measurable disease on scans
Who may not be able to join:
- Dose Escalation part only: People whose cancer is melanoma, a brain tumour, glioblastoma, sarcoma, or pancreatic ductal adenocarcinoma
- Expansion part only: People who have already had more than 3 lines of systemic cancer treatment
- Expansion part only: People with MSS colorectal cancer who also have cancer that has spread to the liver
- People who are pregnant or currently breastfeeding
- People who have received certain other treatments recently, including: biological therapies or immunotherapies (such as monoclonal antibodies) within the past 28 days; chemotherapy, targeted therapy, hormone therapy, or radiation within the past 21 days (or 42 days for certain chemotherapy types called nitrosoureas or mitomycin C); any prior treatment that targeted SIRPα or CD47; systemic steroids or immune-suppressing medicines within the past 14 days; another experimental drug or device within the past 28 days; or a live virus vaccine within the past 28 days
- People with active, untreated cancer that has spread to the brain
- People with an active infection that requires systemic treatment
- People with significant heart problems or reduced heart function
- People currently experiencing side effects from prior cancer treatment rated above a moderate level (Grade 2 or higher)
- People with a history of a serious immune reaction caused by a drug
- People who have previously had a severe allergic reaction to another monoclonal antibody, or to any ingredient in the trial drug
- People who have had major surgery recently (confirm the specific timeframe with the trial site)
- People who have tested positive for HIV, hepatitis B, hepatitis C, or active tuberculosis
- People who have received a transplanted organ or tissue from another person
- People with any other serious ongoing illness that could affect their safety or ability to participate in the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 0031 85 90 26 939
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Escalation Phase: Incidence and severity of dose limiting toxicity (DLT), treatment-emergent adverse events (TEAEs), and changes from baseline in safety parameters; Expansion Phase: Evaluate the clinical response of ADU-1805 plus pembrolizumab administered as an intravenous (IV) infusion.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.